FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|18|4|382-389

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.18, Iss.4, 2018-04, pp. : 382-389

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoisoliquiritigenin Inhibits Tumor Progression by Targeting GRP78-β- catenin Signaling in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 4, 2018-04 ,pp. : 390-399

Bentham Science Publishers

Access to resources Recommend Favorite

Triple-Negative Breast Cancer: Epidemiology and Management Options

By Dawood Shaheenah  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2247-2258

Adis International

Access to resources Recommend Favorite

Subtyping of triple-negative breast cancer: Implications for therapy

By Abramson Vandana G.   Lehmann Brian D.   Ballinger Tarah J.   Pietenpol Jennifer A.  

Cancer, Vol. 121, Iss. 1, 2015-01 ,pp. : 8-16

Blackwell Publishing

Access to resources Recommend Favorite

Advances in the Treatment of Triple-negative Early Breast Cancer

By  

Medicinal Chemistry, Vol. 12, Iss. 3, 2016-05 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 70-80

Bentham Science Publishers

Access to resources Recommend Favorite